Head-to-head · WeighScore
Kova vs myRocky
The verdict
myRocky takes it — 51.4/100 to 44.3/100.
myRocky grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. myRocky is a Canadian-incorporated multi-product telehealth platform (Rocky Health Inc., Ontario) that markets brand-name GLP-1s — Ozempic, Mounjaro, and Wegovy — to US patients, with no compounded products.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Kova | myRocky |
|---|---|---|
| WeighScore | 44.3/100 | 51.4/100 |
| Grade | C | C |
| Scorecard rank | #498 | #487 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #498 · C
Strengths
- Publishes the full price ladder for all three plan terms — intro month and renewal rate — directly in its FAQ
- Medication is included in the plan price, with no separate pharmacy charge
- States plainly that its compounded GLP-1s are 'not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality'
- Companion app tracks weight, protein and side effects, with medication schedule reminders
- You are not charged unless a provider approves treatment
Where it loses points
- At $449 per 4 weeks, the standing 1-month plan is among the most expensive compounded GLP-1 options we track
- The advertised $129 is the 6-month plan's intro month only — that plan then renews at $1,794 every 24 weeks
- Billed every 4 weeks rather than monthly, which is 13 charges a year instead of 12
- Never names which GLP-1 molecule is dispensed — only 'compounded, non-FDA-approved GLP-1 medications'
- No pharmacy or prescribing medical group is named anywhere on the site
Graded #487 · C
Strengths
- Brand-name FDA-approved GLP-1s (Ozempic, Mounjaro, Wegovy) on one platform — no compounded-product risk
- LegitScript Approved
- 42-state coverage with an 8-state expansion roadmap published
- Multi-product platform for patients managing GLP-1 plus sexual health, hair loss, or mental health on one subscription
Where it loses points
- Expensive stacked fees: $99 consult + $99/mo program fee + ~$1,409/mo medication = ~$1,508/mo
- Canadian incorporation (Rocky Health Inc., Mississauga, ON) — verify your state's prescriber holds an active US license
- Listed pharmacy is a Canadian community pharmacy; US-fulfillment supply chain not transparent
- Brand-only — no compounded option for cost-sensitive patients
- $1,409/mo Ozempic is near retail; compare NovoCare ($349/mo Wegovy pen) or LillyDirect ($449–$699/mo Zepbound)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.